OBJECTIVES: Since January 2008, the Czech Republic (CZ) regulation on P&R processes in drugs follows both specific assessment and formal proceeding rules including timelines based on EU Transparency Directive. But only much later (2012/2013), specific methodologies for mandatory budget impact and cost-effectiveness analyses were issued by Czech P&R decision body (State Institute for Drug Control; SUKL) formalizing the SUKL’s position as a national HTA agency for appraisal of medicines. The aim of the present study was to describe how the current status quo affects the actual length of the procedures concerning innovations. METHODS: Lists of administrative proceedings and individual proceeding files, were both accessed via public SUKL web page. First, all proceedings initiated between January 2013 and February 2016 were identified (N = 4,153). Consequently, only P&R proceedings on innovative medicines were selected: the inclusion criteria were strictly limited to first-in-class drugs at their 1^st submission. The selected proceedings (N = 65) were then analysed and followed up to May 10^th